8-K: Equus Total Return Receives NYSE Non-Compliance Notice Due to Low Share Price

Equus Total Return, Inc. was notified by the NYSE that it is not in compliance with listing standards because its average share price fell below $1.00 over a 30-day period.

Summary

• Equus Total Return, Inc. received a notice from the New York Stock Exchange (NYSE) on May 15, 2025, indicating non-compliance with Section 802.01C of the NYSE Listed Company Manual.
• The non-compliance is due to the average closing price of Equus's common stock falling below $1.00 over a consecutive 30 trading-day period.
• The notice does not immediately delist the company's stock.
• Equus plans to notify the NYSE by May 25, 2025, of its intention to address the deficiency and regain compliance.
• The company has a six-month period to regain compliance.
• To regain compliance, Equus needs to achieve a closing share price of at least $1.00 on the last trading day of any calendar month during the cure period and maintain an average closing share price of at least $1.00 over the 30 trading-day period ending on that last day.
• Alternatives being considered include a reverse stock split, subject to stockholder approval at the annual meeting scheduled for June 26, 2025.
• If stockholder approval is required, the price condition will be deemed cured if the price promptly exceeds $1.00 per share and remains above that level for at least the following 30 trading days.
• The company's common stock will continue to be listed on the NYSE during this period, contingent on ongoing compliance with other listing standards.
• The notice is not expected to impact the company's business operations or reporting requirements with the SEC.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the non-compliance notice, but the company is taking steps to address the issue and has time to regain compliance. The potential reverse stock split introduces uncertainty.

Positives

• The notice does not result in immediate delisting of the company's common stock.
• The company has a six-month period to regain compliance.
• The notice is not anticipated to impact the ongoing business operations of the company or its reporting requirements with the SEC.

Negatives

• The company's average stock price has fallen below the NYSE's minimum requirement of $1.00 for continued listing.
• The company is at risk of being delisted if it fails to regain compliance within the six-month cure period.

Risks

• Failure to regain compliance with NYSE listing standards could lead to delisting, which may negatively impact the company's stock price and investor confidence.
• The reverse stock split, if implemented, could be viewed negatively by investors.
• The company's ability to achieve the required stock price may be affected by market conditions and company performance.

Future Outlook

The company intends to regain compliance with NYSE listing standards within the six-month cure period, considering alternatives such as a reverse stock split. The company makes forward looking statements regarding future circumstances that are subject to various risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements including, in particular, the performance of the Company, including our ability to achieve our expected financial and business objectives, and the other risks and uncertainties described in the Company's filings with the SEC.

Industry Context

Many companies face challenges in maintaining share price compliance, especially in volatile markets. Reverse stock splits are a common strategy to address this issue, but their effectiveness can vary.

Comparison to Industry Standards

• Other companies facing similar situations, such as [Comparable Company A] and [Comparable Company B], have also considered reverse stock splits to regain compliance.
• The success of such measures often depends on the underlying financial health and growth prospects of the company.
• Companies like [Comparable Company C] have successfully regained compliance through operational improvements and increased investor confidence.

Stakeholder Impact

• Shareholders may experience dilution if a reverse stock split is implemented.
• The company's reputation and investor confidence could be negatively impacted if it fails to regain compliance.
• Employees may be affected by any potential restructuring or operational changes resulting from the situation.

Next Steps

• Equus will notify the NYSE of its intent to cure the deficiency by May 25, 2025.
• The company will consider alternatives to cure the stock price non-compliance, including a reverse stock split.
• Stockholder approval for a reverse stock split will be sought at the annual meeting on June 26, 2025.
• The company must achieve and maintain a minimum share price to regain compliance within the six-month cure period.

Key Dates

Keywords

NYSE, non-compliance, listing standards, share price, Equus Total Return, reverse stock split, delisting